Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer
CHIMOVIP is a study to determine the best therapeutic strategy in patient with ovarian advanced cancer.
Trial Details
- NCT ID
- NCT03025477
- Phase
- PHASE2
- Sponsor
- Groupe Hospitalier Diaconesses Croix Saint-Simon
- Status
- RECRUITING
- Cancer Type
- Ovarian Cancer
- Interventions
- CC0 - Carboplatin (IV) - Paclitaxel (IV)
- CC0 - Cisplatin (IP) - Epirubicin (IV)
- CC>0 - Carboplatin (IV)- Paclitaxel (IV)
- CC>0 - Cisplatin (IP/IV)- Epirubicin (IV)
- Locations (sample)
- Dijon, France|47.31344,5.01391
- Levallois-Perret, France|48.89389,2.28864
- Paris, France|48.85341,2.3488
- Paris, France|48.85341,2.3488
- Poissy, France|48.92902,2.04952
Key Eligibility Criteria
- Histologically confirmed advanced (FIGO stage III or IV) invasive epithelial ovarian cancer, primary peritoneal cancer, or fallopian-tube cancer. P…
- Initial intervention : debulking surgery or diagnostic surgery in the 3 weeks before inclusion
- Age ≥18 and \< 75 years old.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 before surgery (ECOG ≤ 1 and Lee score \< 6 in patients \> 70 years old).
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Ovarian Cancer Trials on Trialify →